Implantable Loop Recorders for Unexplained Palpitations

Palpitations are common, but a normal 12-lead electrocardiogram (ECG) does not settle the diagnostic question. The tracing captures only a few seconds of cardiac activity, while symptoms may occur unpredictably over weeks or months. A patient can therefore have a normal examination and resting ECG while experiencing paroxysmal atrial fibrillation, supraventricular tachycardia, intermittent bradycardia, pauses, or ventricular arrhythmia.

An implantable loop recorder (ILR), also called an implantable cardiac monitor or insertable cardiac monitor, provides long-term rhythm surveillance beneath the skin. It is especially useful when symptoms are infrequent, external monitoring has been unrevealing, or the potential consequences of a missed arrhythmia justify prolonged observation. Careful patient selection remains essential: the device should answer a meaningful clinical question rather than simply extend testing without a plan.

Why A Normal ECG May Miss The Diagnosis

A resting ECG can identify persistent conduction disease, pre-excitation, prior myocardial injury, a prolonged QT interval, or an established atrial rhythm. It may also reveal clues that change the urgency of assessment. However, a normal tracing between episodes cannot exclude an intermittent rhythm disorder. The diagnostic value of monitoring depends largely on whether the device is recording when symptoms occur.

The history remains the first filter. Clinicians should document the onset and offset of the sensation, its duration, regularity, triggers, associated dizziness or syncope, chest discomfort, breathlessness, and family history of sudden death. A rapid, regular episode that starts and stops abruptly raises a different possibility from brief skipped beats during stress. Medication use, stimulant intake, alcohol, thyroid disease, anaemia, sleep apnoea, and electrolyte disturbance also deserve review.

In Australia, a patient may first present to a GP clinic, an after-hours service, or an emergency department after an episode has already resolved. Someone living in regional New South Wales, Western Australia, or the Northern Territory may face a long trip to an electrophysiology service, making repeated short monitoring appointments impractical. These access realities should be included in the diagnostic strategy without allowing geography to replace clinical risk assessment.

Choosing Between External And Implantable Monitoring

External options remain appropriate for many patients. A 24- or 48-hour Holter monitor suits daily symptoms, while a patch monitor or event recorder can cover several days or weeks. Wearable devices and smartphone ECGs may provide useful rhythm strips when used carefully, although consumer recordings vary in quality and do not replace a clinical diagnosis. If symptoms occur every few days, an external monitor may deliver an answer more quickly and at lower procedural cost.

An ILR becomes more attractive when episodes are unpredictable or separated by long symptom-free intervals. It is inserted through a small incision, usually under local anaesthetic, and can continuously analyse rhythm for several years depending on the model and programming. Patients can activate a recording during symptoms, while automatic algorithms flag events such as pauses, bradycardia, tachycardia, or atrial fibrillation. The stored electrogram must still be reviewed by a trained clinician because algorithmic alerts can be affected by noise, ectopic beats, undersensing, or oversensing.

The device is particularly valuable when there is unexplained syncope or presyncope and an arrhythmic cause remains plausible. For palpitations alone, the threshold should be more individualised. A low-risk patient with fleeting symptoms and no structural heart disease may reasonably begin with reassurance and non-invasive monitoring. Conversely, recurrent abrupt palpitations with near-syncope, significant family history, abnormal imaging, or concerning exertional symptoms may justify early specialist assessment.

Patient Selection And Pre-Implant Assessment

Before implantation, clinicians should establish what result would change management. The question might be whether symptoms correlate with atrial fibrillation, whether a rapid supraventricular rhythm explains recurrent episodes, or whether bradycardia is responsible for falls and presyncope. If the likely outcome would not alter treatment, an ILR may add little value. Baseline investigations commonly include a 12-lead ECG, blood tests guided by the history, echocardiography when structural disease is suspected, and review of previous monitoring.

Shared decision-making should cover the expected diagnostic yield, the possibility of recording symptoms without finding a dangerous rhythm, wound care, infection, bleeding, discomfort, device migration, and the need for follow-up. Patients should understand that an ILR records rhythm rather than providing treatment. It cannot terminate tachycardia, pace a slow heart, or prevent sudden cardiac death. If a clinically important arrhythmia is discovered, a separate intervention may be required.

The broader electrophysiology context also matters. Findings may lead to anticoagulation assessment for atrial fibrillation, an ablation referral for recurrent tachycardia, medication adjustment, pacemaker implantation for significant bradycardia, or additional sudden-death risk evaluation. Research and clinical discussions involving implantable devices should distinguish diagnostic monitors from therapeutic systems; a useful comparison is provided in this report on subcutaneous ICD outcomes, which addresses a very different device purpose.

Implantation, Follow-Up, And Interpretation

Insertion is generally a short day procedure. The monitor is placed beneath the skin, commonly in the left parasternal region, and the incision is closed with sutures, adhesive, or both. Patients receive instructions about keeping the wound clean, recognising redness or discharge, and contacting the treating service for fever, increasing pain, or separation of the wound. Most return to ordinary activities after the wound has healed, subject to local advice.

Remote monitoring can transmit alerts to the clinical team, while patient activation links symptoms with the stored rhythm. The follow-up plan should explain whom to contact during an episode and what to do if symptoms include prolonged chest pain, severe breathlessness, collapse, or ongoing palpitations. An ILR should never delay emergency care. In Australia, arrangements differ between public hospitals, private cardiology practices, and rural outreach services, so patients should receive a clear local pathway rather than assuming a metropolitan model.

Interpretation requires correlation, not just detection. A device may identify atrial high-rate episodes that need confirmation before they are labelled atrial fibrillation. Short runs of ectopy may be harmless, while a slow rhythm during sleep may be physiological in a fit person. Conversely, a symptom-associated pause or sustained tachycardia can be clinically decisive. Every alert should be considered alongside the symptom diary, medications, activity, comorbidities, and the quality of the recorded electrogram.

From Rhythm Evidence To Clinical Action

The greatest benefit of long-term monitoring is a symptom–rhythm correlation that resolves uncertainty. A finding of sinus rhythm during typical palpitations can redirect attention toward ectopy, anxiety, medication effects, reflux, musculoskeletal sensations, or another non-arrhythmic cause. That is still a useful result when it prevents unnecessary antiarrhythmic treatment or invasive procedures. If atrial fibrillation is recorded, stroke risk assessment and management should follow current guidelines rather than the monitor result alone.

When paroxysmal supraventricular tachycardia is documented, referral for electrophysiology assessment and catheter ablation may be appropriate. Clinically important pauses or atrioventricular block can prompt pacing evaluation. Ventricular arrhythmia, exertional syncope, an abnormal echocardiogram, or a concerning family history requires a more urgent and comprehensive pathway. An ILR finding should therefore trigger a structured response, not an isolated label in the medical record.

Some patients have reflex syncope with cardioinhibitory pauses or functional bradycardia. In selected cases, specialist assessment may include therapies beyond conventional observation, including cardioneuroablation review. This is not a routine treatment for unexplained palpitations, and careful phenotyping is essential before considering it. The monitor can contribute objective evidence, but management still depends on the complete clinical syndrome.

Australian practice also requires attention to continuity. A patient who moves between a GP in Brisbane, a private cardiologist in Melbourne, and a public hospital in Tasmania may have records distributed across different systems. Clear documentation of the indication, device model, alert thresholds, remote-monitoring responsibility, and escalation plan helps prevent missed notifications. For patients in remote communities, telehealth can support review, but urgent examination and emergency transport arrangements must remain explicit.

Clinicians, researchers, and trainees working on rhythm monitoring can consult the journal’s author submission guidance when preparing original research, reviews, or clinical education. Rigorous reporting should describe the monitoring duration, activation method, alert criteria, adjudication process, symptom correlation, and subsequent treatment. Thoughtful ILR use turns an elusive complaint into actionable evidence while keeping the patient’s safety, access, and preferences at the centre of care.